Falsified Medicines Directive in a Secondary Care Environment—Impact on Supply Chain

Piotr Merks, Urszula Religioni, Nuno Pinto de Castro, Anna Augustynowicz, Katarzyna Plagens-Rotman, David Brindley, Anna Kowalczuk, Justyna Kaźmierczak, Agnieszka Neumann-Podczaska, Eliza Blicharska, Katarina Fehir Sola, Martin J. Hug, Klaudiusz Gajewski and Paweł Piątkiewicz
Additional contact information
Piotr Merks: Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, 01-938 Warsaw, Poland
Urszula Religioni: School of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland
Nuno Pinto de Castro: Open University Business School, Walton Hall, Kents Hill, Milton Keynes MK7 6AA, UK
Anna Augustynowicz: School of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland
Katarzyna Plagens-Rotman: Institute of Health Sciences, Hipolit Cegielski State University of Applied Sciences, 62-200 Gniezno, Poland
David Brindley: UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), The University of Oxford, Oxford OX2-0JB, UK
Anna Kowalczuk: National Institute of Medicines, 00-725 Warsaw, Poland
Justyna Kaźmierczak: Zdrowit sp. z o.o., Pharmacy Chain, 41-940 Piekary Śląskie, Poland
Agnieszka Neumann-Podczaska: Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, 61-245 Poznan, Poland
Eliza Blicharska: Department of Analytical Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland
Katarina Fehir Sola: Pharmacy of Bjelovar, Petra Preradovića4, 43000 Bjelovar, Croatia
Martin J. Hug: Medical Center–University of Freiburg, 79085 Freiburg, Germany
Klaudiusz Gajewski: Imed Poland Sp. z o.o., 02-819 Warsaw, Poland
Paweł Piątkiewicz: Department of Ophthalmology, Medical University of Warsaw, 02-091 Warsaw, Poland

IJERPH, 2022, vol. 19, issue 6, 1-11

Abstract: The Falsified Medicines Directive (FMD) and the Delegated Regulation (DR) impact the pharmaceutical supply chain. Ahead of the deadline for implementation, in February 2019, every entity of the supply chain had to adapt its operations to the regulatory requirements to be compliant with the directive. This paper analyzes the supply chain of a hospital pharmacy and the impact of the FMD implementation. Furthermore, a cost analysis was performed demonstrating that the FMD increases expenditure in the secondary care environment dispensing operations. Governments should be aware that this regulation will certainly impact public healthcare institutions in the long term.

Keywords: falsified medicines directive; delegated regulation; supply chain; hospital (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/6/3276/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/6/3276/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:6:p:3276-:d:768304

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().